The global leader in surgical support products and services, STERIS plc has agreed to acquire Xodus Medical, a Pennsylvania-based surgical products company, for $2.1 billion. The STERIS acquisition of Xodus Medical will expand STERIS’s healthcare consumables business with products designed to support patient and operating-room staff safety.
The STERIS and Xodus Medical deal will add specialty surgical devices and single-use operating-room supplies to STERIS’s existing healthcare portfolio.
STERIS Corporation, a wholly owned subsidiary of STERIS plc, will acquire all the equity of Xodus Medical. The companies expect to complete the transaction by December 31, 2026.
Why Is STERIS Acquiring Xodus Medical?
The STERIS acquisition of Xodus Medical strengthens STERIS’s position in the healthcare consumables market, where hospitals require a steady supply of products for surgical procedures and infection prevention.
STERIS provides healthcare and life-sciences products and services, including sterilization and infection-prevention solutions. Xodus Medical develops specialized products that address safety needs during surgery.
STERIS President and CEO Dan Carestio expressed that “Xodus Medical’s product portfolio complements and expands STERIS’s offering, particularly by adding consumables used in the operating room.” He also highlighted the company’s record of double-digit growth, ongoing product development, and established commercial team.
Combining complementary products could also give Xodus Medical access to STERIS’s established commercial network.
What Products Will Xodus Medical Bring to STERIS?
Founded in 1993, Xodus Medical develops and manufactures medical devices designed to improve surgical patient safety.
Xodus’ flagship product is the Pink Pad patient-positioning system, which helps secure and stabilize patients on operating tables. Proper positioning can help address the risk of patients slipping during surgery.
Xodus Medical’s portfolio also includes:
- Electrosurgical accessories: Products used during surgical procedures involving electrical energy.
- Medication labels: Supplies that help identify medications in clinical settings.
- Anti-fog products: Items designed to maintain visibility through surgical lenses.
- Sharps safety products: Devices that support safer handling of needles and other sharp surgical instruments.
These Xodus Medical’s products will broaden the range of operating-room consumables available through the STERIS healthcare portfolio.
The STERIS acquisition of Xodus Medical expands STERIS’s product offering, although the companies have not announced specific changes to product availability following the transaction.
Financial Details of The STERIS Acquisition of Xodus Medical
Several financial components determine the overall cost of the Xodus Medical acquisition.
Purchase price: $2.1 billion at closing
Estimated net purchase price: ≅ $1.8 billion
Estimated net purchase price: ≅ $1.8 billion
Anticipated cash tax benefits: ≅ $300 million in net present value
Projected 2026 revenue: ≅ $245 million
Potential additional payment: Up to $150 million, linked to 2028 performance targets
Goldman Sachs & Co. LLC serves as STERIS’s financial adviser, with Jones Day providing legal counsel. J.P. Morgan advises Xodus Medical financially, while Morgan, Lewis & Bockius LLP provides legal counsel.
How Will the STERIS Xodus Medical Acquisition Impact the Healthcare Industry?
The STERIS acquisition of Xodus Medical adds to ongoing healthcare mergers and acquisitions as medical technology and healthcare suppliers expand their product portfolios.
For hospitals and surgical teams, the deal brings together STERIS’s infection-prevention expertise and Xodus Medical’s specialized surgical safety products under one corporate group.
STERIS may also use its established customer relationships to support Xodus’s growth, although the companies have not confirmed specific commercial integration plans.
The STERIS and Xodus Medical deal remains subject to approval and completion. Its longer-term impact will depend on how STERIS integrates Xodus Medical’s products and operations into its existing business.
